U.S. Stem Cell Clinic: Patient Based Webinar
The U.S. Stem Cell Clinic is founded on the principle belief that the quality of life for our patients can be improved through stem cell therapy. We are dedicated to providing safe and effective...
By: U.S. Stem Cell Clinic
Read the original:
What is Stem Cell Therapy- Trinity Spine and Wellness Center New Port Richey
http://www.Trinity-Spine.com -727-372-9922 what is Stem Cell Therapy for back pain? Watch this video to see how Stem Cell Therapy can immediately help your chronic neck and back pain. Visit our website ...
By: Anderson Flanders
Read more:
What is Stem Cell Therapy- Trinity Spine and Wellness Center New Port Richey - Video
Stem Cell Therapy for Pain - Now Available at Columbia Pain Management
http://regenerativepaintherapy.com Call: 541-716-6469 Columbia Pain Management Can Help You Get Your Life Back. Stem Cell Therapy for Pain - Now Available at Columbia Pain Management.
By: Trey Rigert
Go here to see the original:
Stem Cell Therapy for Pain - Now Available at Columbia Pain Management - Video
U.S. Stem Cell Clinic: Stem Cell Banking
The U.S. Stem Cell Clinic is founded on the principle belief that the quality of life for our patients can be improved through stem cell therapy. We are dedicated to providing safe and effective...
By: U.S. Stem Cell Clinic
Read more from the original source:
U.S. Stem Cell Clinic: How long will my recovery take?
Our U.S. Stem Cell Clinic procedure is minimally invasive and patients walk out within 3 hours in most cases. As a result recovery time is very quick. Many patients will experience soreness...
By: U.S. Stem Cell Clinic
More:
U.S. Stem Cell Clinic: How long will my recovery take? - Video
U.S. Stem Cell Clinic: How is Stem Cell Therapy Performed?
Our U.S. Stem Cell Clinic will perform outpatient procedures using a process in which we isolate a patient #39;s own stem cells from either their own adipose fat tissue or bone marrow. Approximately...
By: U.S. Stem Cell Clinic
Read the original:
U.S. Stem Cell Clinic: How is Stem Cell Therapy Performed? - Video
U.S. Stem Cell Clinic: What is Stem Cell Therapy?
What is Stem Cell Therapy? Stem cell therapy attempts to harness the body #39;s own healing potential by isolating stem cells from one location of the body (fat tissue or bone marrow) and relocating...
By: U.S. Stem Cell Clinic
More:
U.S. Stem Cell Clinic: When should I expect to see results?
It is important to note that we are treating patients with their own adult stem cells, therefore each treatment and response is unique to that patient. No guarantee can be made of what results...
By: U.S. Stem Cell Clinic
See original here:
U.S. Stem Cell Clinic: When should I expect to see results? - Video
New Delhi, April 11 (IANS): Though there are many stem cell therapies that are being explored, bone marrow transplant is the only one which has been tried and tested, a noted scientist has said.
Stem cell therapy is the use of stem cells to treat or prevent a disease or condition. Stem cells are undifferentiated cells of an organism which are capable of giving rise to indefinitely more cells of the same type, and from which certain other kinds of cells arise by differentiation.
"Most of the stem cell therapies like the ones which can successfully treat Parkinson's disease and methods of ortho-reconstruction are in experimental stages," noted cellular biologist Jyotsna Dhawan said in a special lecture on 'Stem cells: Myths and Realities' at the India International Centre (IIC) here Friday evening.
Dhawan, a senior scientist at the Centre for Cellular and Molecular Biology, Hyderabad, said stem cells are a potential source of repair of other tissues and can be very useful in treating genetic and inherited diseases. She said stem cells are specially useful in treating genetic disorders associated with blood like haemophilia and thalassemia.
"But, major ethical issues arise when embryonic stem cells (cells taken from a foetus) are used for therapy," she added.
On the many myths associated with stem cells, Dhawan said: "All these myths stem from the hope that we are able to tackle many of these diseases through stem cells".
Experiments are on to try and find cures for debilitating and terminal diseases like muscular dystrophy and cancer through stem cell therapy.
Stay updated wherever you go with Daijiworld.com and Daijiworld 24X7 tv channel mobile apps. CLICK HERE to download it for your device. (available on Android and IOS)
See more here:
(MENAFN - ProactiveInvestors)
Regeneus (ASX: RGS) has achieved a key milestone with the manufacture of its off-the-shelf stem cell therapy product Progenza for its First-in-Human trial for the treatment of osteoarthritis.
The company is on track to receive ethics approval and commence recruitment for the trial in the first-half of 2015.
Adding interest the company highlighted the benefit of using adipose or fat tissue over other tissue types by demonstrating the capacity to produce millions of therapeutic doses of Progenza from a single donor.
The production of commercial quantities of stem cells from a single donor is critical to maximise dose-to-dose consistency chief executive officer John Martin said.
This scale of production will minimise clinical trial and regulatory risks while reducing the cost of the final product.
One of the key advantages for manufacturing Progenza at industrial scale is that it uses stem cells sourced from adipose or fat tissue.
Adipose tissue is readily available from donors in large quantities and has significantly higher stem cells per gram of tissue than other tissue sources such as bone marrow or cord tissue.
Also adipose derived stem cells show greater capacity for expansion than stem cells from other tissue types.
Progenza adipose derived stem cells are adult stem cells they are not genetically modified like induced pluripotent stem cells (iPSC).
Read the original here:
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (BioLife or the Company), today announced that Cardio3 BioSciences, a leader in engineered cell therapy with clinical programs initially targeting indications in cardiovascular disease and oncology, has embedded the Companys clinical grade CryoStor cryopreservation freeze media in its ongoing Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) phase III clinical trial in Europe and Israel and the pending CHART-2 phase III clinical trial to be conducted in the United States.
CHART-1 (Congestive Heart Failure Cardiopoietic Regenerative Therapy) is a patient prospective, controlled multi-centre, randomized, double-blinded Phase III clinical trial comparing treatment with C-Cure to a sham treatment. The trial has recruited 240 patients with chronic advanced symptomatic heart failure. The primary endpoint of the trial is a composite endpoint including mortality, morbidity, quality of life, Six Minute Walk Test and left ventricular structure and function at nine months post-procedure.
Dr. Christian Homsy, CEO of Cardio3 BioSciences, commented on the selection of CryoStor by stating, We evaluated several possible freeze media formulations for our clinical cell therapy product development and manufacturing. CryoStor and BioLife best met our preservation efficacy, product and supplier quality, and customer support requirements.
As of January 2015, BioLife management estimates that the Companys CryoStor freeze media and HypoThermosol cell and tissue storage/shipping media have been incorporated into at least 175 customer clinical trials of novel cellular immunotherapies and other cell-based approaches for treating and possibly curing the leading causes of death and disorders throughout the world. Within the cellular immunotherapy segment of the regenerative medicine market, BioLife's products are embedded in the manufacturing, storage, and delivery processes of at least 75 clinical trials of chimeric antigen receptor T cells (CAR-T), T cell receptor (TCR), dendritic cell (DC), tumor infiltrating lymphocytes (TIL), and other T cell-based cellular therapeutics targeting solid tumors, hematologic malignancies, and other diseases and disorders. A large majority of the currently active private and publicly traded cellular immunotherapy companies are BioLife customers.
Mike Rice, BioLife Solutions CEO, remarked; We are honored to be able to supply our clinical grade CryoStor cell freeze media for Cardio3 Biosciences phase III clinical trials. Congestive heart failure is a leading cause of death and C-Cure is a novel and potentially life-saving, cell-based therapy that offers hope to millions of patients throughout the world. We are very well positioned to participate in the growth of the regenerative medicine market, with our products being used in at least 75 phase II and over 20 phase III clinical trials of new cell and tissue based products and therapies.
About Cardio3 Biosciences Cardio3 BioSciences is a leader in engineered cell therapy with clinical programs initially targeting indications in cardiovascular disease and oncology. Founded in 2007 and based in the Walloon region of Belgium, Cardio3 BioSciences leverages research collaborations in the USA with the Mayo Clinic (MN, USA) and Dartmouth College (NH, USA). The Companys lead product candidate in cardiology is C-Cure, an autologous stem cell therapy for the treatment of ischemic heart failure. The Companys lead product candidate in oncology is CAR- NKG2D, an autologous CAR T-cell product candidate using NKG2D, a natural killer cell receptor designed to target ligands present on multiple tumor types, including ovarian, bladder, breast, lung and liver cancers, as well as leukemia, lymphoma and myeloma. Cardio3 BioSciences is also developing medical devices for enhancing the delivery of diagnostic and therapeutic agents into the heart (CCath) and potentially for the treatment of mitral valve defects. Cardio3 BioSciences shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD. To learn more about Cardio3 BioSciences, please visit c3bs.com
Read the original:
Back Pain Stem Cell Therapy Doctors Tampa
http://Trinity-Spine.com (727) 372-9922 Stem Cell Therapy Doctor Reviews Everyone was so nice and helpful. They calmed my nerves about having to get this done, and even had really late hours...
By: Anderson Flanders
Continued here:
Brenda Simmons hugs her horse Little Brother at her ranch in Granby late last month. Simmons and Little Brother have had stem cell therapy on their legs, preventing debilitating issues for both. (Andy Cross, The Denver Post)
Colorado Parks and Wildlife officers removed about 100 prairie dogs. (Courtesy Malia Reeves)
Your daily resource for late-breaking news, upcoming events, the Denver weather forecast, Denver traffic information, and the stories that will be talked about on Wednesday, April 8, 2015. Download our iPhone, iPad and Android apps for breaking news throughout the day.
1. THE HORSE FIX IS IN
The story of how researchers are using some horse sense to innovate stem cell joint therapies. Close to home, horses are leading humans into new territory, inspiring not only patients but researchers in regenerative therapies at Colorado State University in Fort Collins and the University of Colorado Hospital in Denver.
2. NOBLE TO CUT 100 ENERGY JOBS
Noble Energy, Colorado's second largest oil producer, said Tuesday that in the face of low prices it is reorganizing its operations cutting 100 jobs in Denver and Greeley.
3. 100 SEIZED PRAIRIE DOGS IN RODENT LIMBO
State wildlife agents and police officers seized about 100 prairie dogs from a Castle Rock woman's garage Tuesday morning, weeks after they were trapped at a controversial shopping mall development site.
4. POUNCED IN PRISON
See more here:
Daily Digest: The horse stem cell fix is in for Colorado, and 9 other stories
When Little Brother came up lame six years ago at the age of 8, Brenda Simmons took her horse from one veterinarian specialist to another to find a fix.
Injections of the horse's stem cells into a lower leg joint and tendons relieved his pain and returned full function to a horse that had been unridable.
"He was better than ever, and he's still going strong," the 58-year-old Granby resident said. "I asked the vet, 'Can you do that for me?' "
She couldn't, but a physician in Edwards, Dr. Scott Brandt, did treat her with stem cells.
After crippling pain had sidelined her for years, she said, injection of her own stem cells and other living cell products, taken from her bone marrow and fat tissue, has restored the former runner and skier to a more active life over the past year. She had already had one knee-replacement surgery, but she now believes she can avoid a second one.
( | )
"It's not mainstream. It's still in development," Brandt said of treatment that can cost $8,000 to $12,000 and isn't covered by insurance. "But it will happen in our lifetimes. This will delay or prevent many surgeries."
Many orthopedic specialists remain skeptical of these treatments unsure where proven advancements end and experimentation begins in doctors' offices using people's stem cells along with other biological components.
Yet leading researchers say there is real potential, especially if the Food and Drug Administration eases restrictions on culturing adult stem cells in labs for reinjection.
Even as these alternatives to surgical fixes for knees, backs, hips, shoulders and elbows are being developed, joint surgeries are booming as Americans resist being stiff and sore.
See the article here:
Colorado researchers use horse sense to innovate joint therapies
Freeport, Grand Bahama (PRWEB) April 08, 2015
Amy was searching for a way to get her type 1 diabetes under control when she was referred to Okyanos, the leader in cell therapy. After years of regular visits to the hospital for diabetes, neuropathy and fibromyalgia, she was looking for something that would help her lead a healthier, more normal life. No stranger to pain, Amy has had more than her share of treatments, including meditation, biofeedback, physical therapy and medications, getting her to a point of functional with very bad flare ups.
Amy experienced a condition called diabetes burnout which can occur when one gets tired of the endless attention diabetes care requires. After such a period, just 19 and a sophomore in college, Amy woke up one day with swollen feet and persistent horrible pain. She went home to Florida for spring break and ended up in the hospital for six weeks with a neuropathy diagnosis. Neuropathy is common in older diabetics but at a young age, the diagnosis threatened what shred of normal she had left.
I couldnt sleep with a blanket and it was hard to have anything on my feet. I had to shake the bed to distract myself from the pain. My life consisted of sitting in a bath tub for 6 hours a day running water over my feet, Amy explained.
After deciding to undergo adult stem cell therapy, Amy said her doctor was extremely encouraging and really interested. However, Amy stated, Nothing could prepare me for how nice the facility was. Everything was explained and when it came time for the procedure, I had no doubts. It was great.
After some initial hesitation and a set of expectations, Amy says she couldnt be happier with her results. I can now sleep with a blanket. I dont shake the bed the entire night. My feet arent a constant thought in the back of my mind anymore. The other day it was about 4pm and I realized, I havent thought about my feet once today, she shared.
In addition to changes in her daily life, Amys post-cell therapy successes are still coming in. When Amy saw her doctor a few weeks after treatment, and a regular check-up, they discovered Amys A1C levels (test to measure average blood glucose level) were significantly lower.
My doctor hadnt ever dealt with this kind of situation before. I think what really blew her mind was the fact that my A1C has gone down so much. Before the cell therapy, I was at 8.9. Now Im at a 7.8. I havent been that low in years, said a delighted Amy.
According to the American Diabetes Association, over 20 million diagnosed Americans suffer from diabetes and roughly 1.25 million are type 1. Diabetes remains the 7th leading cause of death in the US.
Adult stem cell therapy has emerged as a new treatment alternative for those with auto-immune conditions like diabetes and are restricted in activities they can no longer do but are determined to live a more normal life. Okyanos cell therapy uses a unique blend of adult stem and regenerative cells derived from a patients own fat tissue, thereby utilizing the bodys own natural biology to heal itself.
Go here to see the original:
Beverly Hills, California (PRWEB) April 07, 2015
Dr. Raj, the top Orthopedic Surgeon in Beverly Hills and Los Angeles, is now offering stem cell therapy to heal chronic tendonitis. The treatment works exceptionally well for those suffering from tendonitis of the rotator cuff, achilles, elbow and knee. For more information and scheduling, call (310) 247-0466.
As a pioneer in regenerative medicine, Dr. Raj has been helping patients with degenerative arthritis achieve relief and avoid joint replacements for years with stem cell procedures. By adding the procedures for tendonitis, Dr. Raj is now helping patients avoid potentially risky surgeries and get back to being more active for soft tissue related pain.
"Surgery for tendonitis is often not 100% successful for patients, and the rehabilitation period may take six months," states Dr. Raj. "With the stem cell therapy, pain relief is quick and athletes get back to sports faster!"
Regenerative medicine for tennis elbow has been shown in research studies to be effective at relief and helping avoid surgery. A 2013 study out of South Florida showed that 28 out of 30 patients with chronic tennis elbow avoided surgery and got back to being very active.
For several years in a row, Dr. Raj has been named the top orthopedic doctor in Los Angeles and Beverly Hills. He is an ABC News Medical Correspondent as well as a WebMD Medical Expert.
Hundreds of patients have benefited from stem cell procedures with Dr. Raj at Beverly Hills Orthopedic Institute. They come from all over Southern California, along with throughout the country. Call (310) 247-0466 for scheduling stem cell therapy with an orthopedic surgeon Beverly Hills trusts and respects.
Read the original:
(MENAFN - ProactiveInvestors) () a biotechnology company announced the expansion of its cancer stem cell intellectual property portfolio to include targeting of the gene NR2F2 (also known as COUP-TFII) a closely related family member to the cancer stem cell gene NR2F6 with the filing of two patent applications.
Patent application #14588374 is for treatment of myelodysplastic syndrome (MDS) by inhibition of NR2F2 and patent application # 14588373 is for methods and compositions for treatment of cancer by inhibition of NR2F2 the San Diego California-based company said in a statement today.
Patent application #14588374 covers methods compositions and treatment protocols for the treatment of MDS. This patent application also covers induction of differentiation or stimulation of apoptosis as a result of NR2F2 inhibition to reduce the state of MDS and/or in other embodiments to inhibit or revert progression to leukemic states Regen said.
Patent application #14588373 covers utilizing of gene silencing technologies pertaining to suppression of the nuclear receptor NR2F2 for use as cancer stem cell inhibitors as well as cancer stem cell pathway inhibitors and methods of using such compounds to treat cancer.
These new patent applications add to the company's existing portfolio of intellectual property covering therapeutics that can be used as differentiation therapy a new form of cancer treatment that works by instructing cancer stem cells to mature in to normal cells that have a limited lifespan.
This intellectual property will compliment other intellectual property in the gene silencing of cancer stem cells therapeutics platform including in-house and acquired IP from the University of Toronto for the cancer stem cell gene NR2F6 (also known as EAR-2) and the company's CTCFL technology also known as BORIS).
We are working on establishing an area of expertise in gene silencing of cancer stem cell target genes that builds upon a licensing agreement with Benitec Biopharma for use in conjunction with their shRNA gene silencing platform chief executive officer David Koos said in the statement.
This allows us to take advantage of synergisms by establishing strengths and programs that we can use to comprehensively target the important genes in the cancer stem cell space. This will lead to economies of scale in therapy development.
The cancer stem cell is the most important and sought after cellular target of cancer therapy. Not every cancer cell within a tumour is able to divide. Cancer stem cells are the cells within the tumour that can divide an infinite number of times and are the cells within the tumour that allow a tumour to maintain its cancerous ability therefore it is important to target those cells specifically.
"Patent protection is also essential for thoroughly protecting the Company's space in this field chief scientific officer Thomas Ichim said in the statement.
More:
Regen BioPharma expands Its differentiation therapy of cancer stem cells platform
Brazilian researchers announced progress toward the use of implanted stem cells as a treatment for Parkinsons disease.
Investigations at the DOR Institute for Research and Education (IDOR) and Federal University of Rio de Janeiro (UFRJ) report that their newly developed therapy reduced symptoms in mice.
Using an FDA approved substance for treating stomach cancer, S.K. Rehen and colleagues were able to grow dopamine-producing neurons derived from embryonic stem cells. The cells remained healthy and functional for as long as 15 months after implantation into mice restoring motor function without forming tumors.
Parkinsons, which affect as many 10 million people in the world, is caused by a depletion of dopamine-producing neurons in the brain.
Current treatments include medications and electrical implants in the brain which causes severe adverse effects over time and fail to prevent disease progression.
In the current study, researchers build upon past investigations that have indicated the transplantation of embryonic stem cells improves motor functions in animal models. However, until now, the procedure has shown to be unsafe, because of the risk of tumors upon transplantation.
To address this issue, the researchers pre-treated undifferentiated mouse embryonic stem cells with mitomycin C a drug already prescribed to treat cancer. The substance blocks the DNA replication and prevents the cells to multiply out of control.
The researchers used mice modeled for Parkinsons. The animals were separated in three groups. The first one, the control group, did not receive the stem cell implant. The second one, received the implant of stem cells which were not treated with mitomycin C and the third one received the mitomycin C treated cells.
After the injection of 50,000 untreated stem cells, the animals of the second group showed improvement in motor functions but all of them died between three and seven weeks later. These animals also developed intracerebral tumors.
In contrast, animals receiving the treated stem cells showed improvement of Parkinsons symptoms and survived until the end of the observation period of 12 weeks post-transplant with no tumors detected. Four of these mice were monitored for as long as 15 months with no signs of pathology.
See original here:
Degenerated/herniated lumbar discs 1 year after stem cell therapy by Harry Adelson, N.D.
Bill describes his result one year after bone marrow stem cell therapy by Dr. Harry Adelson for low back pain caused by a degenerated and herniated lumbar disc.
By: Harry Adelson, N.D.
Visit link:
Degenerated/herniated lumbar discs 1 year after stem cell therapy by Harry Adelson, N.D. - Video
Life-changing results: Sandra Sharman is a private stem cell patient. Photo: Meredith O'Shea
Last week, Suzie Palmer, 44, travelled from her home in NSW to the Gold Coast for her second round of stem cell treatments for multiple sclerosis. OnTuesday morning,the wheelchair-bound poet underwent liposuction.
By 2.30pm, stem cells had been partially separated from her abdominal fat, suspended in plasma, and injected intravenously. Her doctor, Soraya Felix, is a cosmetic surgeon and molecular biologist with a sideline in regenerative medicine.
Palmer, a relentlessly upbeat and positive person, says the treatments have helped her cope better with heat, improved her mobility and flexibility and otherwise made her "feel like a normal human being". She has, she says, managed a few steps with a walker, still a long way from "running about, which is my dream".
Poster girl: Suzie Palmer is undergoing stem cell therapy for MS. Photo: Edwina Pickles
The rapidly growing stem cell industry is aglow with similarly positive testimonials, notably on behalf of practitioners who offer little documented scientific evidence of their success.
Advertisement
Suzie Palmer is literally the poster girl for stem cell tourism within Australia. You can find her smiling sweetly, along with Dr Felix, on the Facebook page of a group called the Adult Stem Cell Foundation. She is one of an unknown number of unwell Australians pinning their hopes on an unregulated industry that is now under review by the Therapeutic Goods Administration.
The TGA public consultation, which closed earlier this month, was prompted by long-standing concerns raised by Stem Cells Australia that a loophole in the regulations has allowed dozens of doctors across Australia to provide experimental treatments without the ethics committee oversight that registered clinical trials are subject to. These treatments invariably cost $10,000 and up. The loophole is this: while the use of donor stem cells in therapies is tightly regulated, the use of a patient's own stem cells is not.
Professor Martin Pera is the program leader of Stem Cells Australia, which is administered by the University of Melbourne and includes scientists from Monash University, the Walter and Eliza Hall Institute for Medical Research, the Florey Institute and the CSIRO, among others. They are engaged in a seven-year Australian Research Council project to answer the big questions about stem cells and the potential for reliable therapies.
Read more:
Is a loophole in stem cell law helping new therapy to thrive, or allowing dubious science?